Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials

EMBRACE: Exercising Together

NCT06049355
Recruiting
Conditions Breast Carcinoma, Prostate Carcinoma
Phase PHASE2
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests how well an exercise intervention, Exercising Together, works in preventing declines in physical and mental health in couples during radiation treatment for cancer. Treatments for cancer can cause side effects such as fatigue as well as strain on relationships. Exercising Together is a partnered exercise program that adds communication, collaboration and support between partners during exercise to fortify the relationship and amplify the benefits of physical training. Exercising Together program may be effective on the mental and physical health of couples during radiation treatment for cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Exercise Intervention — Undergo Exercise Together exercise program, a supervised group exercise program delivered online, using a live remote format
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Other: Educational Intervention — Receive educational materials

Primary Outcomes

  • Physical functioning (Baseline, Months 2, Month 4, and Month 6)
  • Anxiety (Baseline, Month 1, Month 2, Month 4, and Month 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-04-18
Completion: 2028-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: OHSU Knight Cancer Institute
Collaborators: Oregon Health and Science University, National Cancer Institute (NCI)
Principal Investigators:
  • Kerri Winters-Stone (PRINCIPAL_INVESTIGATOR) - OHSU Knight Cancer Institute
Contact Information
Study Contact:
Carolyn Guidarelli
503-494-0444
exercise@ohsu.edu
Carolyn Guidarelli
503-494-0444
exercise@ohsu.edu
OHSU Knight Cancer Institute
Kerri Winters-Stone
OHSU Knight Cancer Institute
Interventions
  • Other: Exercise Intervention — Undergo Exercise Together exercise program, a supervised group exercise program delivered online, using a live remote format
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Other: Educational Intervention — Receive educational materials
Study Locations (1 sites)
OHSU Knight Cancer Institute, Portland, Oregon 97239 United States
Eligibility Criteria
Inclusion Criteria: * INTERVENTION (SURVIVORS) INCLUSION * Histologically confirmed prostate cancer or breast cancer without evidence of metastatic disease * Confirmed by review of the electronic medical record (EMR) and subsequently recorded in Survivor Health History. In cases where the EMR isn't clear, their Oregon Health \& Science University (OHSU) provider will be contacted for confirmation. For non-OHSU patients, we'll initially collect their cancer health history by a self-report questionnaire and confirm when we receive the survivor's outside medical record (through a signed Release of Information) * Scheduled to receive radiation therapy for curative intent * Confirmed by review of the EMR and subsequently recorded in Survivor Health History. In cases where the EMR isn't clear, their OHSU provider will be contacted for confirmation/ For non-OHSU patients, we'll initially collect their cancer health history by a self-report questionnaire and confirm when we receive the survivor's outside medical record (through a signed Release of Information) * Co-residing with an intimate partner or spouse who is willing to participate * Confirmed by self-report on the Demographic Questionnaire * INTERVENTION (SURVIVORS AND PARTNERS) INCLUSION * 18 years of age and older * For survivors: confirmed by review of the date of birth as documented in the Electronic Medical Record (EMR) and subsequently recorded in Survivor Health History. For non-OHSU patients, we'll collect their age by self-report on the Survivor Health History * For partners: confirmed by self-report on the Health History Questionnaire * \< 2 structured strength training sessions for less than 30 minutes per week in the last month * Confirmed by self-report on Health History Questionnaire * Home internet sufficient for videoconferencing * Confirmed by staff review of Internet Connectivity Screening Guide with the participants and outcome recorded in a CRF * Signed informed consent * Confirmed by completion of e-Consent in REDCap * Willing to be randomized into either study arm and adhere to study protocol * Confirmed verbally with the participant and response documented in the Participant Tracking database * IMPLEMENTATION INCLUSION * Be one of these key stakeholders: patient, spouse/partner, healthcare providers, or administrator * Verbal informed consent following receipt of an Information Sheet Exclusion Criteria: * INTERVENTION (SURVIVORS AND PARTNERS) EXCLUSION * Cognitive difficulties that preclude answering the survey questions, participating in the exercise classes or performance tests, or providing informed consent * In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigator, Kerri Winters-Stone * A medical condition, movement or neurological disorder, or medication use that contraindicates participation in moderate intensity exercise. Specific contraindications include the following: poorly controlled diabetes, recent cardiac event, neuromuscular disease, untreated orthostatic hypertension, recent surgery, acute hernia, acute rheumatoid arthritis, severe memory disorders, severe balance disorder, inability to ambulate without a walker or wheelchair, inability to stand for 3 minutes, severe hearing or vision problem * Confirmed by a combination of reviewing the EMR, self-report on the Health History Questionnaire, Charlson Comorbidity Index questionnaire, and/or by physician clearance. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible. For Spouse/Partner: must answer \'No\' to American College of Sports Medicine pre-participation screening questions. If spouse/partner answers \'Yes\' to either question they may be required to obtain physician clearance prior to becoming eligible. Physician clearance may also be requested at the discretion of the principal investigator.
Conditions Breast Cancer, Liver Metastases
Phase Not Applicable
Enrollment 720
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.

Design

Study type: Observational Observational model: Case Control Time perspective: Other

Primary Outcomes

  • 5-years overall survival (2018-2023)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2018-04-01
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 720 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Information
Study Contact:
Amelia Mattia, MD
+390453015
amelia.mattia01@icatt.it
Amelia Mattia, MD
+390453015
amelia.mattia01@icatt.it
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Interventions
N/A
Study Locations (1 sites)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio 00168 Italy
Eligibility Criteria
Inclusion Criteria: * \> 18 years old * BCLM * BCLM and extra-hepatic disease * Any treatment * Ability to understand and sign the informed consent Exclusion Criteria: * Inability to provide the informed consent * Patient who underwent Best Supportive Care or Palliation
Conditions Asthma in Children, Asthma
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Nature of potential dysbiosis, interrelation of the different microbiomes of the respiratory tract, and potential role of the immune system in the pathogenesis of severe asthma in infants, and its evolution under treatment. Exploring and understanding these data is to improve patient care and discover new therapeutic targets. The aim is to open up prospects for therapeutic studies, such as the use of azithromycin as an immunomodulator in infant asthma, the results of which are discordant.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Blood sample — An additionnal volume of blood will be collected at inclusion and at each follow-up visit
  • Other: Expectoration — Expectoration will be collected at inclusion and at each follow-up visit
  • Other: Nasopharyngeal swab — A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum

Primary Outcomes

  • description of microbiomes from bronchoalveolar fluids (Inclusion)
  • description of microbiomes from nasopharyngeal samples (Inclusion)
  • description of microbiomes from sputum samples (Inclusion)
  • description of microbiomes from bronchoalveolar fluids (at 3 months)
  • description of microbiomes from nasopharyngeal samples (at 3 months)
  • description of microbiomes from sputum samples (at 3 months)
  • description of microbiomes from bronchoalveolar fluids (at 6 months)
  • description of microbiomes from nasopharyngeal samples (at 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-26
Completion: 2026-09-26
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Rouen
Principal Investigators:
  • PETAT Hortense (PRINCIPAL_INVESTIGATOR) - University Hospital, Rouen
Contact Information
Study Contact:
David Mallet
02 32 88 82 65
secretariat.DRC@chu-rouen.fr
Hortense PETAT
Rouen University Hospital
Interventions
  • Other: Blood sample — An additionnal volume of blood will be collected at inclusion and at each follow-up visit
  • Other: Expectoration — Expectoration will be collected at inclusion and at each follow-up visit
  • Other: Nasopharyngeal swab — A nasopharyngeal swab will be collected at inclusion and at each follow-up visit after an induced sputum
Study Locations (1 sites)
Rouen University Hospital, Rouen, France
Eligibility Criteria
Inclusion Criteria: * Infants less than 24 months old * Follow-up by a pneumo-pediatrician for severe asthma in infants * Requiring etiological investigations and assessment of severity in day hospitalization, including bronchial fibroscopy (HAS 2009) * Parent informed of the research and having signed consent Exclusion Criteria: * Prematurity \<32 WA * Congenital heart disease with significant left to right shunt * Chronic respiratory disease other than infant asthma (cystic fibrosis, bronchiolitis obliterans) * Antibiotic therapy in progress or administered the seven days preceding the date of inclusion (day hospitalization) * Refusal of bronchial fibroscopy
Conditions Breast Cancer, Cardiotoxicity
Phase PHASE2
Enrollment 130
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study to find out whether an intensive approach to treating high blood pressure during breast cancer treatment is safe and more effective than standard blood pressure treatment at lowering blood pressure levels and the risk of cardiotoxicity in patients with cancer. Other studies have shown lowering blood pressure improves the health of patients. However, these studies have not included people with cancer. The PROTECT trial is testing a treatment strategy regarding intensive versus standard SBP goals, and is not testing specific medications.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: antihypertensive medications — One or more of the following medications may be used in both randomization groups to achieve SBP goals: * Angiotensin converting enzyme inhibitors (ACEI) * Angiotensin receptor blockers (ARBs) * Beta-blockers (BB) * Thiazide-type diuretics * Calcium channel blockers * Aldosterone antagonists * Alpha1-receptor blockers. * Direct vasodilators * Loop diuretics
  • Diagnostic Test: Blood pressure measurement — Home BP Monitoring (HBPM)-Throughout the study period, patients will perform HBPM at baseline, month 6, and month 12 (end of treatment). At each of these timepoints, HBPM will be performed for 7 days with 2 morning and 2 evening readings for each day (measured 1-min part).
  • Diagnostic Test: Echocardiogram — At baseline, month 6, and month 12
  • Other: Symptom-limited cardiopulmonary exercise test — Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.
  • Other: Quality of Life Measures — FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.
  • Diagnostic Test: Biomarkers — Research blood samples will be collected at baseline, 3 months, and 6 months

Primary Outcomes

  • mean change in systolic blood pressure (SBP) from baseline to 12 months (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-08-18
Completion: 2029-05-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Anthony Yu, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Anthony Yu, MD
212-639-7932
yua3@mskcc.org
Jennifer Liu, MD
212-639-8220
Anthony Yu, MD
212-639-7932
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Interventions
  • Other: antihypertensive medications — One or more of the following medications may be used in both randomization groups to achieve SBP goals: * Angiotensin converting enzyme inhibitors (ACEI) * Angiotensin receptor blockers (ARBs) * Beta-blockers (BB) * Thiazide-type diuretics * Calcium channel blockers * Aldosterone antagonists * Alpha1-receptor blockers. * Direct vasodilators * Loop diuretics
  • Diagnostic Test: Blood pressure measurement — Home BP Monitoring (HBPM)-Throughout the study period, patients will perform HBPM at baseline, month 6, and month 12 (end of treatment). At each of these timepoints, HBPM will be performed for 7 days with 2 morning and 2 evening readings for each day (measured 1-min part).
  • Diagnostic Test: Echocardiogram — At baseline, month 6, and month 12
  • Other: Symptom-limited cardiopulmonary exercise test — Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.
  • Other: Quality of Life Measures — FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.
Study Locations (7 sites)
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Female assigned at birth * Biopsy proven breast cancer (stage I-IV) * Treatment with therapy anthracycline-based chemo (with or without HER2-targeted therapy), with \>/= 2 cycles of anthracycline chemotherapy planned. * SBP ≥130 mm Hg * Willing and able to comply with the requirements of the protocol. * Participant must have and be willing to use their bluetooth enabled wifi or cellular mobile device * (For participants in the CPET cohort): Able to complete an acceptable baseline CPET, in the absence of high-risk ECG findings or other inappropriate response to exercise as determined by the PI, as defined by any of the following criteria: * Achieving a plateau oxygen consumption, concurrent with an increase in power output; * A respiratory exchange ratio ≥ 1.10; * Attainment of maximal predicted heart rate, as defined by a peak heart rate within 10bpm of the age predicted maximal heart rate (220 - Age\[years\]); * Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale. Exclusion Criteria: * eGFR \< 30 ml/min/1.73m2 (based upon Cockcroft-Gault, etc.) * Individuals with arm circumference too large to allow accurate BP measurement with available BP devices * Inability to accurately measure blood pressure in at least one arm (e.g., bilateral upper extremity lymphedema) * Cardiac comorbidity, including any of the following: * Acute coronary syndrome within 3 months prior to randomization. * Symptomatic heart failure (NYHA class III/IV) within past 6 months * History of stroke * Cardiac transplantation * Other medical disorder or condition that in the opinion of the investigator would impair the subject's ability to participate or adhere to study interventions * (For participants in the CPET cohort): Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing: * Acute myocardial infarction (within 30 days of any planned study procedures), * Unstable angina * Uncontrolled arrhythmias causing symptoms or hemodynamic compromise, * Symptomatic severe aortic stenosis * Recurrent syncope * Active endocarditis * Acute myocarditis or pericarditis * Acute pulmonary embolus or pulmonary infarction (within 3 months of any planned study procedures) * Thrombosis of lower extremities (within 3 months of any planned study procedures) * Suspected dissecting aneurysm * Uncontrolled asthma * Pulmonary edema * Room air desaturation at rest ≤85% * Respiratory failure * Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis) * Mental impairment leading to inability to cooperate.

Penn Medicine Healthy Heart

NCT06062394
Recruiting
Conditions Hypertension, Hyperlipidemias
Phase NA
Enrollment 1980
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for Penn Medicine patients in West/Southwest Philadelphia and Lancaster.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Triple

Interventions / Regimen

  • Behavioral: Penn Med Healthy Heart Program — Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.

Primary Outcomes

  • Difference in mean Systolic Blood Pressure (SBP) (6-month period)
  • Difference in mean LDL-c (6-month period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-11
Completion: 2026-12
Eligibility
Age: 35 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1980 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pennsylvania
Principal Investigators:
  • Kevin Volpp, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Pennsylvania
Contact Information
Study Contact:
Kayla Clark, MPH
215-746-4428
kayla.clark@pennmedicine.upenn.edu
Laurie Norton, MA, MBE
Laurie.Norton@pennmedicine.upenn.edu
Laurie A Norton, MA, MBE
215-573-8799
Laurie.Norton@pennmedicine.upenn.edu
Penn Medicine
Interventions
  • Behavioral: Penn Med Healthy Heart Program — Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
Study Locations (1 sites)
Penn Medicine, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * On the Penn Medicine Primary Care Service Line registry * Last 2 Blood Pressure readings with Systolic Blood Pressure \>=140 from any outpatient encounter in the last 12 months AND * ASCVD dx OR ASCVD risk score ≥10% OR Diabetes dx OR A1c ≥6.5 in last year OR Diabetes registry OR Last LDL ≥190 in past five years AND * Not on a statinor PCSK9, Inclisiran OR on a Low-intensity/moderate-intensity statin) with LDL \>100 Exclusion Criteria: * Patients on PCSK9 inhibitors * Documented statin allergy/ or intolerance in the EMR * Pregnancy * Breast feeding * Markedly shortened life expectancy including: 1. metastatic cancer 2. hospice 3. End Stage Renal Disease 4. Congestive Heart Failure 5. Dementia * Is a non-English speaker requiring a translator * Patients who do not have a cell phone

Gastric Pathophysiology in Diabetes

NCT06068114
Recruiting
Conditions Diabetes Mellitus, Type 1, Diabetes Mell...
Phase Not Applicable
Enrollment 120
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a comprehensive pathophysiological study assessing various gastric functions in patients with diabetes mellitus. The investigators aim to examine the stomach with various measurement devices to gain information about its different functions and malfunctions. After the initial measurements, the examinations will be repeated after a year in each patient. Changes in the measurement values will be examined and their relations to each other and to the overall health of the patients will be investigated. For example it is hypothesised that diabetic patients also suffering from functional dyspepsia or gastroparesis will also show some changes in the function of the pyloric muscle.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Pyloric distensibility (At baseline and after 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-10-05
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute for Clinical and Experimental Medicine
Collaborators: Poliklinika Agel, Dopravni zdravotnictvi a.s.
Contact Information
Study Contact:
Eva Evinová, MD
eva.evinova@vtn.agel.cz
Eva Evinová, MD
eva.evinova@vtn.agel.cz
Nemocnice AGEL Ostrava-Vítkovice a. s.
Marek Buzga, PhD
marek.buzga@osu.cz
University Hospital Ostrava
Interventions
N/A
Study Locations (5 sites)
Nemocnice AGEL Ostrava-Vítkovice a. s., Ostrava, 703 00 Czechia
University Hospital Ostrava, Ostrava, 708 52 Czechia
Institute for Clinical and Experimental Medicine, Prague, 14021 Czechia
Military University Hospital Prague, Prague, 16902 Czechia
University Hospital Trnava, Trnava, 917 02 Slovakia
Eligibility Criteria
Inclusion Criteria (diabetic group): * Diabetes mellitus type I or II, minimal duration of the disease 3 years, minimal duration of specific treatment (drugs, insulin) 2 years Exclusion Criteria (diabetic group): * Diabetes mellitus type II being treated with a diet only * Severe acute decompensation of diabetes (uncontrolled diabetes) necessitating hospitalization * Concomitant treatment with more than one prokinetic agent * Active treatment with opioids or a history of treatment with opioids within 12 months before enrolment * Previous esophageal or major gastric surgery (e.g. esophageal myotomy, esophagectomy, antireflux surgery, Billroth I or II gastric resection, gastric pull-through, pyloromyotomy, pyloroplasty, gastric electrical stimulation) * Organic pyloric (or intestinal) obstruction (fibrotic stricture, etc.) * Severe coagulopathy * Esophageal or gastric varices and /or portal gastropathy * Advanced liver cirrhosis * Pregnancy or puerperium * Malignant or pre-malignant gastric diseases (dysplasia, gastric cancer, GIST): patients with a history of such disease after its cure are eligible for enrolment * The presence of a rumination syndrome or eating disorders (anorexia nervosa, bulimia). In case of doubts, a psychiatric examination will be performed. * Systemic connective tissue disorder * Inability to obtain informed consent * Any other condition, which in the opinion of the investigator would interfere with study requirements
Conditions Adolescent Depression
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Starting at puberty, female adolescents are nearly three-times more likely to develop internalizing disorders, like depression, while male adolescents are two-times more likely to develop externalizing disorders, like attention deficit hyperactivity disorder (ADHD). This divergence between the sexes during puberty suggests sex-specific pathways of risk and differential effects of sex hormones. The purpose of this research is to determine: 1) sex-specific neural and endocrine features of the pubertal transition that may mediate sex differences in adolescent mood disorders, and 2) the neurophysiological basis of susceptibility to hormone change during puberty.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Healthy Minds Program — The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.

Primary Outcomes

  • CES-DC Score Over Time (up to Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-24
Completion: 2027-12
Eligibility
Age: 11 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: Foundation of Hope, North Carolina
Principal Investigators:
  • Elizabeth Andersen, PhD (PRINCIPAL_INVESTIGATOR) - University of North Carolina, Chapel Hill
Contact Information
Study Contact:
Kayla Jensen, BS
919-445-6815
nerdlab@unc.edu
Kayla Jensen, BS
919-445-6815
nerdlab@unc.edu
Carolina Crossing B, Suite 1
Elizabeth Andersen, PhD
Carolina Crossing B, Suite 1
Interventions
  • Behavioral: Healthy Minds Program — The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
Study Locations (1 sites)
Carolina Crossing B, Suite 1, Chapel Hill, North Carolina 27517 United States
Eligibility Criteria
Inclusion Criteria: * Between the ages of 11 and 14 * Have their own personal mobile device and capability to download the MyCap and Healthy Minds apps * Experienced a stressful life event within the last year, or endorse moderate depression (defined by a CES-DC score 16 or higher) Exclusion Criteria: * Previous experience with the Healthy Minds Program * Regular meditation practice * Current or history of manic episodes, psychotic symptoms, or current suicidal intent * Taking any form of exogenous hormones or intrauterine device (IUD) within one month of participation in the study * Taking medications that directly alter cardiovascular or neurological function
Conditions Type 2 Diabetes, Heart Failure, Reduced ...
Phase EARLY_PHASE1
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not dependent upon insulin or influenced by insulin resistance.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ketone Monoester (KE) — Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits

Primary Outcomes

  • Cardiac Efficiency after acute dose (Left-ventricular function) (1.5 hours to 24 hours)
  • Cardiac Efficiency after chronic dosing (Left-ventricular function) (1.5 hours to 7 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2024-01-16
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center at San Antonio
Collaborators: National Center for Advancing Translational Sciences (NCATS)
Principal Investigators:
  • Carolina Solis-Herrera, MD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center at San Antonio
Contact Information
Study Contact:
Carolina Solis-Herrera, MD
210-567-4900
solisherrera@uthscsa.edu
Carolina Solis-Herrera, MD
210-567-4900
solisherrera@uthscsa.edu
University of Texas Health Science Center at San Antonio
Interventions
  • Drug: Ketone Monoester (KE) — Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits
Study Locations (1 sites)
University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 United States
Eligibility Criteria
Inclusion Criteria: * Subjects must be on a stable dose of guideline-directed medications for Heart Failure (HF). * Patients will have an established diagnosis of HF before the screening visit, documented by an acceptable imaging modality in the last 6 months. * Age = 18-80 y * Body Mass Index (BMI) =23-38 kg/m2 * Glycated hemoglobin (HbA1c) = 6.0-10.0% * Blood Pressure (BP) \< 145/85 mmHg * Estimated Glomerular Filtration Rate (eGFR) \> 30 ml/min•1.73 m2 * For women of child-bearing age (WOCBA) willingness to use contraception, if applicable. Exclusion Criteria: * Patients treated with Sodium-Glucose Transport Protein (SGLT2i's) or medications that may impair heart function or acutely worsen glycemic control will be excluded. * Pregnancy, lactation, or plans to become pregnant. A negative pregnancy test will be performed before each Magnetic resonance imaging (MRI) study to assess current status. * Allergy/sensitivity to study drugs or their ingredients. * Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * Inability or unwillingness of individual or legal guardian/representative to give written informed consent. * Subjects with a history of cancer (except basal or squamous cell cancer that has been resolved/remission for 5 years) * Cardiovascular event within the last 3 months * Major organ or metabolic diseases, or physical limitations that will not allow the subject to complete the study.
Conditions Diabetes Mellitus Type 2, Diabetes Melli...
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Kuwait and the Gulf Region lack large longitudinal studies that identify risk factors dictating the onset of prediabetes and the progression to diabetes. The Kuwait Diabetes Epidemiology Program (KDEP), previously carried out at Dasman Diabetes Institute, was designed to develop a research dataset providing a random sampling of the Kuwaiti population. The dataset contained primarily epidemiology data for healthy, prediabetic and diabetic individuals; and was designed to serve as a resource for research and prevention programs on obesity, diabetes, and metabolic syndrome. The KDEP data supported research studies at DDI to delineate risk factors for metabolic disease from the views of genetics, biochemistry, immunology and epidemiology. One of the main limitations of the KDEP study was that it only captured a cross-sectional view of the participants in terms of diabetes status as well as lack of extensive phenotyping. In the current study, the investigators aim to perform a follow up on the non-diabetic KDEP cohort participants to enrich it with detailed physiological, genetic, biochemical and environmental data and thereby to establish an association between the development of diabetes and multidimensional risk factors. the investigatorswill also recruit family members of the KDEP and RA2010-005 participants as well as others with family history of diabetes to better identify familial patterns in risk factors. The outcome of this effort will immediately serve as a scientific baseline for developing prevention strategies for the control and management of obesity, diabetes and associated complications such as cardiovascular disease. Given the magnitude of the social and economic burden of diabetes on the Kuwaiti population, longitudinal data from the KDEP Follow-up study should play an important role in establishing the incidence of T2D progression in non-diabetic participants that were enrolled in the initial study as well as of progression to diabetes complications. This will have a positive impact on the population by providing clinicians with data to better target their patient management and by supporting policy and decision-makers in developing comprehensive health promotion programs to control these diseases at the national level.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Conversion to Diabetes (5 years)
  • Conversion to Pre-Diabetes (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-05-23
Completion: 2027-05-23
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dasman Diabetes Institute
Contact Information
Study Contact:
Mohamed Abu-farha, PhD
+96560660804
mohamed.abufarha@dasmaninstitute.org
Fahd Al-Mulla, MD, PhD
2224 2999
fahd.almulla@dasmaninstitute.org
Mohamed Abu-Farha, PhD
Dasman Diabetes Institute
Interventions
N/A
Study Locations (1 sites)
Dasman Diabetes Institute, Kuwait City, 40000 Kuwait
Eligibility Criteria
Inclusion Criteria: People who participated in the original KDEP study. People with prediabetes. Type 2 Diabetes patients. Exclusion Criteria: People are unwilling to sign the consent form. Pregnant women.
Conditions Healthy Participants, Breast Cancer
Phase Not Applicable
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the feasibility of using See.d instrument and SBS slides for preparation of plasma and cytological samples from whole blood. Forty-five participants will be enrolled (20 healthy volunteers and 25 metastatic breast cancer patients) and each participant will be asked to provide a blood sample.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Evaluation of White Blood Cells adhered on SBS slides (1 day (at the blood draw))
  • SBS slides stability (1 day (at the blood draw)])
  • cfDNA quality control (1 day (at the blood draw))
  • Feasibility of using See.d SBS slides for subsequent analysis (1 day (at the blood draw))
  • Feasibility of using See.d plasma for subsequent analysis (1 day (at the blood draw))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-06
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tethis S.p.A.
Principal Investigators:
  • Luca Mazzarella, MD (PRINCIPAL_INVESTIGATOR) - IEO Hospital
Contact Information
Study Contact:
Luca Mazzarella, MD
+39 0294375111
luca.mazzarella@ieo.it
Luca Mazzarella, MD
+39 0294375111
luca.mazzarella@ieo.it
IEO
Interventions
N/A
Study Locations (1 sites)
IEO, Milan, 20132 Italy
Eligibility Criteria
Inclusion Criteria: * General (all participants) * Participants is willing and able to give and sign a written informed consent * Aged 18 or above * Specific for metastatic breast cancer patients * Female for metastatic breast cancer patients, aged 18 or above * Histological confirmation of breast cancer * Presence of at least one non-bone metastasis * Disease assessed to be in clinical or radiologic progression to the last line of treatment, as evaluated by the investigator * The biopsy, when recommended by the oncologist, is scheduled within 4 weeks after the date of blood withdrawal * Last biopsy or any other minor surgical procedure was perfomed at least 7 days before blood withdrawal * Known Bilirubin level ≥ 2 mg/dL on a blood sample collected within 7 days from the enrolment. If unavailable, it is not necessary to assess bilirubin * Specific for healthy participants * Both sexes for healthy volunteers, aged 18 or above * Healthy participants who visit the site for reason other than cancer diagnosis (including breast cancer). Exclusion Criteria: * Ongoing infections requiring antibiotic or antiviral treatment * Previous history of a blood cancer or an invasive non-BC apart from cancers treated with curative intent at least 3 years previously with no recurrence since diagnosis with the exception of non-melanoma skin cancer. For healthy participants also includes breast cancer * Undergone major surgery \< 4 weeks prior to the time of blood collection * Initiated a new line of treatment after disease progression at the time of blood or tissue biopsy collection * Presence of known severe coagulation or haematological disorder * Pregnancy * For metastatic breast cancer patients: histological confirmation of a Triple Negative Breast Cancer (TNBC)
Conditions Depression
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Participation in the CALYPSO project will be offered to all patients with severe depression hospitalized in the adult psychiatry department of Lille CHU. An initial visit will provide a standardized clinical assessment with: a medical history and history of the disease, a standardized structured Hamilton scale interview (scale with a score from 0 to 21; the higher the score, the more severe the depression) to assess the severity of depression, and a search for the different features of severe depression (melancholic, psychotic, anxious, catatonic, seasonal) using DSM-5 criteria (list of criteria to be validated to determine the type of clinical features). When assessing the severity of depression using the Hamilton scale interview, the patient will be seated in an armchair 2 to 3 meters from a camera on a tripod, positioned behind the clinician and enabling the entire interview to be recorded and, in particular, several observable and measurable psychiatric signs and symptoms, known as objective markers. From the video will be extracted face landmark and pose parameter using state-of-the-art open source software (Mediapipe) to analyze patients' emotional facial expressions and spatial movements. Moreover, a microphone will be used to capture the audio synchronously with the video. Speech will be automatically transcoded using state-of-the-art Automatic Speech Recognition system (DeepSpeech) to enable analysis of voice-related parameters (voice timbre, prosody, sound intensity). A recording of physical activity (3-axis accelerometer sensor; 32 Hz) and emotional reactivity (heart rate in beats per minute 1Hz; electrodermal activity 4 Hz; skin temperature in degrees 4 Hz; Empatica© bracelet) and brain activity (cerebral blood flow change index 10Hz; pulse rate in bpm 10Hz; 3-axis acceleration and angular velocity of the head 10Hz via functional Near-Infrared Spectroscopy (fNIRS) using a HOT-2000 wearable headset) will also be offered to the patient to complete the assessment. The Hamilton scale interview and recording of objective markers will be carried out weekly during the patient's hospitalization in an examination room specifically equipped for the project, on the second floor of the Fontan Hospital, in the psychiatry department of the Lille University hospital. Longitudinal follow-up will be carried out with assessments at 3, 6 and 12 months after hospital discharge, including the Hamilton scale interview and recording of objective markers (i.e., emotional facial expressions, spatial movements, voice timbre, prosody, sound intensity, physical activity, heart rate, electrodermal activity, skin temperature).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Behavioral: New computer vision methods — Clinical interview: Hamilton scale using multi-modal sensors (cameras, audio, bracelet, fNIRS)

Primary Outcomes

  • Severity of depression and clinical characteristics. (The primary outcome is measured at the initial visit, then at assessments at 3, 6 and 12 months after hospital discharge.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-30
Completion: 2027-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Lille
Principal Investigators:
  • Ali AMAD, MD, PhD (PRINCIPAL_INVESTIGATOR) - University Hospital, Lille
Contact Information
Study Contact:
Ali AMAD, MD, PhD
3 20 44 44 60
ali.amad@chu-lille.fr
DRI
320444145
drs.promotion@chu-lille.fr
Hôpital Fontan 1 - CHU de Lille
Interventions
  • Behavioral: New computer vision methods — Clinical interview: Hamilton scale using multi-modal sensors (cameras, audio, bracelet, fNIRS)
Study Locations (1 sites)
Hôpital Fontan 1 - CHU de Lille, Lille, 59000 France
Eligibility Criteria
Inclusion Criteria: * Male or female, over 18 years of age * with severe depression as defined by DSM-5 criteria hospitalized in the adult psychiatry department of Lille University Hospital. * Socially insured * Patient willing to comply with all study procedures and duration. Exclusion Criteria: * Refusal to participate after receiving clear and fair information about the study * Pregnant or breast-feeding women * Person deprived of liberty or under guardianship or curatorship
Conditions Breast Cancer, Quality of Life, Physical...
Phase NA
Enrollment 110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Local intervention trial for the evaluation of improvements in patient-reported Quality of Life and treatment satisfaction, in breast cancer patients (BCP), as a result of flexible treatment planning supported by REBECCA-collected real-world data, in comparison with standard care

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: REBECCA system (smartwatch + mobile app use) — Patients will be trained in the use of the REBECCA system, which will provide in-depth information about their lifestyle (including physical activity levels, dietary habits, sleep quality and social mobility), as well as of their online behaviour (with outcome indicators of anxiety, PTSD and depression development) and self- or companion-reported measures of emotional state and quality of life. Based on the additional information, exploiting the enhanced monitoring capabilities of the REBECCA system, the supervising clinicians will be given the opportunity to continuously evaluate the progress of the patients, allowing them to schedule up to 3 phone-based consultation sessions in the first 12 months of treatment

Primary Outcomes

  • Resting quality (18 months follow up since enrolment with a monthly measurement)
  • Stress level (18 months follow up since enrolment with a monthly measurement)
  • Stress level related to illness (18 months follow up since enrolment with a monthly measurement)
  • Pain level of the last 24 hours (18 months follow up since enrolment with a monthly measurement)
  • Tiredness level of the last 24 hours (18 months follow up since enrolment with a monthly measurement)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-01
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia
Contact Information
Study Contact:
Tania Fleitas, MD, PhD
+34 616315091
tfleitask@gmail.com
Hospital Clínico Universitario de Valencia
Interventions
  • Device: REBECCA system (smartwatch + mobile app use) — Patients will be trained in the use of the REBECCA system, which will provide in-depth information about their lifestyle (including physical activity levels, dietary habits, sleep quality and social mobility), as well as of their online behaviour (with outcome indicators of anxiety, PTSD and depression development) and self- or companion-reported measures of emotional state and quality of life. Based on the additional information, exploiting the enhanced monitoring capabilities of the REBECCA system, the supervising clinicians will be given the opportunity to continuously evaluate the progress of the patients, allowing them to schedule up to 3 phone-based consultation sessions in the first 12 months of treatment
Study Locations (1 sites)
Hospital Clínico Universitario de Valencia, Valencia, 46010 Spain
Eligibility Criteria
Inclusion Criteria: * Before patient registration, written informed consent must be given according to national and local regulations. * Participants have had histologically proven stage I-III breast cancer undergoing endocrine treatment (with or without prior chemotherapy) no more than 12 months prior to randomization. * Be between 18 and 75 years of age. * Have increased life expectancy beyond the initial 3 months post-treatment initiation. * Have the ability to understand protocol, participate in testing and willingness to sign a written informed consent. * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. Exclusion Criteria: * Patients that are not willing to sign an informed consent form